Steven J. O'Day, MD is the Chief Medical Officer at Agenus. He is a board-certified medical oncologist.
Dr. O’Day’s medical training was at Johns Hopkins in Baltimore and the Dana Farber Cancer Institute in Boston. In 1994 Dr. O’Day came to Los Angeles to found the Medical Oncology Division of The John Wayne Cancer Institute in partnership with the world-class Surgical Oncology faculty and of The John Wayne Cancer Institute. Dr. O’Day was a founding member of The Angeles Clinic and Research Institute in Santa Monica, California.
Dr. O’Day is recognized as one of the preeminent melanoma and immunotherapy specialists in the world, and combines expert clinical care with teaching and leading clinical research. He lectures extensively, both nationally and internationally. He has been at the forefront of new drug development in melanoma over the last three decades. Dr. O’Day played a leadership role in the development of the breakthrough immune checkpoint inhibitor ipilimumab as well as the anti-PD1 antibodies pembrolizamab and nivolumab. In addition, he has participated in the development of the MAPK inhibitors vemurafinib, dabrafinib and trametinib. Dr. O’Day currently leads a solid tumor immunotherapy clinical trials group at the John Wayne Cancer Institute specializing in novel immunotherapy combinations.
Dr. O’Day has been a principal investigator on over 200 clinical trials including several large, international Phase III trials. He has published more than 200 manuscripts, abstracts and reviews in prestigious journals such as The New England Journal of Medicine (NEJM), Journal of Clinical Oncology (JCO), Blood, Journal of American Medical Association (JAMA), Cancer, Lancet Oncology and the Journal of the National Cancer Institute. Dr. O’Day serves on multiple pharmaceutical and biotech advisory boards and as a consultant for drug development programs.
Dr. O’Day has served on the ASCO Education Committee (Melanoma) and the ASCO Communications Committee. He has also served on the ASCO International Development and Education Award (IDEA) Working Group where he has mentored IDEA grant recipients.
Dr. O’Day’s medical training was at Johns Hopkins in Baltimore and the Dana Farber Cancer Institute in Boston. In 1994 Dr. O’Day came to Los Angeles to found the Medical Oncology Division of The John Wayne Cancer Institute in partnership with the world-class Surgical Oncology faculty and of The John Wayne Cancer Institute. Dr. O’Day was a founding member of The Angeles Clinic and Research Institute in Santa Monica, California.
Dr. O’Day is recognized as one of the preeminent melanoma and immunotherapy specialists in the world, and combines expert clinical care with teaching and leading clinical research. He lectures extensively, both nationally and internationally. He has been at the forefront of new drug development in melanoma over the last three decades. Dr. O’Day played a leadership role in the development of the breakthrough immune checkpoint inhibitor ipilimumab as well as the anti-PD1 antibodies pembrolizamab and nivolumab. In addition, he has participated in the development of the MAPK inhibitors vemurafinib, dabrafinib and trametinib. Dr. O’Day currently leads a solid tumor immunotherapy clinical trials group at the John Wayne Cancer Institute specializing in novel immunotherapy combinations.
Dr. O’Day has been a principal investigator on over 200 clinical trials including several large, international Phase III trials. He has published more than 200 manuscripts, abstracts and reviews in prestigious journals such as The New England Journal of Medicine (NEJM), Journal of Clinical Oncology (JCO), Blood, Journal of American Medical Association (JAMA), Cancer, Lancet Oncology and the Journal of the National Cancer Institute. Dr. O’Day serves on multiple pharmaceutical and biotech advisory boards and as a consultant for drug development programs.
Dr. O’Day has served on the ASCO Education Committee (Melanoma) and the ASCO Communications Committee. He has also served on the ASCO International Development and Education Award (IDEA) Working Group where he has mentored IDEA grant recipients.
Speaking In
11:00 AM - 11:45 AM (EST)
Monday, February 6
Immuno-oncology therapies have revolutionized the treatment of many cancers over the last decade,…
South Broadway Ballroom